Welcome to our dedicated page for BioCardia SEC filings (Ticker: BCDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioCardia, Inc. SEC filings document a clinical-stage biotechnology and medical-device business focused on cell therapies and related delivery technologies for cardiovascular and pulmonary disease. Recent Form 8-K reports cover Regulation FD disclosures and other events involving CardiAMP clinical data, FDA and PMDA regulatory interactions, the Helix transendocardial delivery catheter, and patent protection for Heart3D Fusion Imaging software.
The company’s filings also record annual operating results, research and development activity, liquidity-related financial disclosures, and Nasdaq continued-listing compliance matters. These documents frame BCDA’s public-company record around product-development programs, regulatory pathways, intellectual property, capital and listing status, risk disclosures, and corporate reporting obligations.
BioCardia, Inc. filed an initial ownership report showing no securities held by the reporting director. A Form 3 was filed for an individual who serves as a director of BioCardia, Inc. (ticker BCDA) for an event dated 12/02/2025. The filing indicates that the form is filed by one reporting person and includes a remark stating that no securities are beneficially owned. An Exhibit 24 power of attorney is referenced, authorizing the signatory to sign on behalf of the reporting person.
BioCardia, Inc. (BCDA) reported an organizational update. The company announced in an 8-K that, on November 24, 2025, it issued a press release appointing Farhan Shahab as Vice President of Quality. This role typically oversees and supports quality systems and compliance for products and operations, which is important for companies operating in regulated medical and life science markets.
The press release describing the appointment is included as Exhibit 99.1, and the company notes that this information is being furnished, not filed, under securities laws, meaning it is provided for disclosure purposes without triggering certain liability provisions.
BioCardia, Inc. filed a current report to furnish its latest quarterly results update. On November 12, 2025, the company issued a press release announcing its financial results for the quarter ended September 30, 2025, and attached that release as an exhibit.
The press release is provided as Exhibit 99.1 and is treated as "furnished" rather than "filed" under securities law, which limits certain legal liabilities and incorporation by reference into other SEC documents unless specifically cited.
BioCardia (BCDA) reported an operational milestone: it announced the first patient enrolled at Henry Ford Health in its ongoing Phase 3 CardiAMP HF II clinical trial for patients with “ischemia heart failure of reduced ejection fraction.”
The announcement was made via a press release furnished as Exhibit 99.1. The information is being furnished under Item 8.01 and is not deemed filed under the Exchange Act.
BioCardia (BCDA) scheduled its 2025 annual meeting for 9:00 a.m. PT on December 2, 2025 at Wilson Sonsini in Palo Alto. Stockholders of record as of October 8, 2025 may vote; there were 10,612,734 shares outstanding on the record date.
Stockholders will vote on: (1) the election of three Class III directors; (2) an amended and restated 2016 Equity Incentive Plan to extend the plan to October 31, 2035, change the “evergreen” to 4.0% of outstanding shares added on the meeting date and each fiscal year start, and limit incentive stock option capacity; and (3) ratification of PKF San Diego, LLP as auditor for 2025. The filing also includes a non-binding advisory vote on executive compensation.
Based on shares outstanding on the record date, the initial increase upon approval would be 424,509 shares. As of November 3, 2025, approximately 95,000 shares remained available under the current plan. Audit fees to PKF were $278,000 in 2024 and $261,000 in 2023. Internet/telephone voting closes at 11:59 p.m. ET on December 1, 2025.
BioCardia (BCDA) announced the first patient was enrolled at the University of Wisconsin School of Medicine and Public Health in its ongoing Phase 3 CardiAMP HF II clinical trial. The update was disclosed under Item 8.01 as a furnished report, and a press release is included as Exhibit 99.1 dated October 30, 2025. The information is furnished, not filed, under the Exchange Act.
BioCardia, Inc. filed an amended Q2 2025 10‑Q solely to add the CEO/CFO certifications omitted from the original filing; no other changes were made.
For the quarter ended June 30, 2025, the company reported a net loss of $2.049 million on operating expenses of $2.051 million. Cash and cash equivalents were $980,000 and stockholders’ equity was a deficit of $(1.886) million. Management states there is “substantial doubt” about continuing as a going concern, noting existing cash is not sufficient beyond October 2025. Shares outstanding were 5,504,802 as of June 30, 2025.
Research and development expense was $1.368 million and selling, general and administrative was $683,000. Subsequent to quarter‑end, the company updated its ATM capacity on July 8, 2025 and sold 296,422 shares for gross proceeds of $769,000 through August 8, 2025. The company also disclosed a Nasdaq notice with an extension to regain equity compliance by September 29, 2025. There were 5,801,224 common shares outstanding as of August 8, 2025.
BCDA filed a prospectus supplement updating its at‑the‑market offering program for common stock through H.C. Wainwright & Co. The supplement sets a new maximum aggregate amount of $5,309,253 that may be sold under the program, after effectiveness and subject to offering conditions.
The company notes it has previously received approximately $3.9 million of gross proceeds from sales under the same program. Eligibility is based on an aggregate market value of non‑affiliate shares of approximately $20.1 million, calculated using 8,846,053 non‑affiliate shares at a $2.27 per‑share price as of September 11, 2025, and is constrained by Form S‑3 General Instruction I.B.6 (one‑third cap). During the 12‑month period ending on the date hereof, the company sold approximately $1.4 million pursuant to I.B.6.
BioCardia, Inc. set its 2025 Annual Meeting of Stockholders for Tuesday, December 2, 2025 at 9:00 a.m. Pacific Time, to be held at Wilson Sonsini Goodrich & Rosati in Palo Alto, California. The company established the close of business on October 8, 2025 as the record date for stockholders entitled to receive notice of and vote at the meeting.
Stockholders who wish to submit proposals for inclusion in the company’s proxy statement under SEC Rule 14a-8, nominate directors, or bring other business at the meeting must ensure their notices are received at BioCardia’s Sunnyvale headquarters by October 17, 2025, and comply with SEC rules, Delaware law, and the company’s bylaws. Stockholders intending to use the universal proxy process to solicit proxies for their own director nominees must also provide the required Rule 14a-19 notice by October 17, 2025.
BioCardia, Inc. announced that on October 2, 2025 it received formal written notice from The Nasdaq Stock Market staff that the company has regained compliance with Listing Rule 5550(b)(1). As a result, the company's common stock will continue to be listed on The Nasdaq Stock Market. The filing states a press release describing the action is attached as Exhibit 99.1 to the current report. The notice signals Nasdaq’s staff has accepted whatever corrective steps the company previously took to meet the Equity Rule and preserves the company’s ongoing access to Nasdaq’s market for its common shares.